Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BVS NASDAQ:EYE NASDAQ:LMAT NASDAQ:LQDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$6.18-5.2%$6.65$6.02▼$14.38$507.65M0.84383,242 shs526,076 shsEYENational Vision$24.21-0.2%$23.05$9.56▼$25.67$1.92B1.271.91 million shs1.81 million shsLMATLeMaitre Vascular$81.04-0.2%$82.52$71.42▼$109.58$1.84B0.82101,135 shs126,468 shsLQDALiquidia Technologies$17.68-5.4%$15.11$8.26▼$20.33$1.60B0.142.40 million shs3.31 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus-5.21%-5.94%-9.78%-15.80%-11.84%EYENational Vision-0.21%-3.24%+0.21%+84.25%+67.43%LMATLeMaitre Vascular-0.25%-1.69%-3.35%+2.97%-6.73%LQDALiquidia Technologies-5.40%-9.80%+46.60%+11.69%+48.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBVSBioventus3.1292 of 5 stars3.40.00.00.02.63.31.3EYENational Vision2.8336 of 5 stars2.32.00.03.33.40.80.0LMATLeMaitre Vascular2.9547 of 5 stars2.23.03.30.02.12.51.3LQDALiquidia Technologies3.3796 of 5 stars4.51.00.00.01.84.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 2.75Moderate Buy$13.75122.49% UpsideEYENational Vision 2.60Moderate Buy$24.18-0.12% DownsideLMATLeMaitre Vascular 2.33Hold$97.8320.72% UpsideLQDALiquidia Technologies 3.00Buy$26.8952.09% UpsideCurrent Analyst Ratings BreakdownLatest BVS, EYE, LMAT, and LQDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025EYENational VisionRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.007/23/2025EYENational VisionWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $24.007/22/2025LMATLeMaitre VascularBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform7/8/2025EYENational VisionUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.007/8/2025EYENational VisionNational BanksharesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$30.007/8/2025EYENational VisionBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$17.00 ➝ $30.007/7/2025BVSBioventusCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$12.006/18/2025EYENational VisionBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.006/12/2025LQDALiquidia TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$23.00 ➝ $25.006/11/2025LQDALiquidia TechnologiesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $23.006/2/2025LQDALiquidia TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$567.70M0.89$0.49 per share12.58$2.80 per share2.21EYENational Vision$1.82B1.05$1.63 per share14.83$10.37 per share2.33LMATLeMaitre Vascular$226.26M8.09$2.38 per share34.01$15.00 per share5.40LQDALiquidia Technologies$14M107.96N/AN/A$0.91 per share19.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus-$156.23M-$0.48N/A13.43N/A-7.11%15.61%4.01%N/AEYENational Vision-$28.50M-$0.33N/A89.673.44-1.40%3.44%1.40%8/6/2025 (Estimated)LMATLeMaitre Vascular$44.04M$1.9840.9337.352.1419.96%13.53%9.78%8/5/2025 (Estimated)LQDALiquidia Technologies-$130.39M-$1.58N/AN/AN/A-903.80%-177.91%-60.15%8/6/2025 (Estimated)Latest BVS, EYE, LMAT, and LQDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025EYENational Vision$0.12N/AN/AN/A$469.21 millionN/A8/6/2025Q2 2025LQDALiquidia Technologies-$0.43N/AN/AN/A$3.90 millionN/A8/5/2025Q2 2025LMATLeMaitre Vascular$0.57N/AN/AN/A$62.48 millionN/A5/8/2025Q1 2025LQDALiquidia Technologies-$0.42-$0.45-$0.03-$0.45$3.23 million$3.12 million5/7/2025Q1 2025EYENational Vision$0.32$0.34+$0.02$0.18$510.30 million$510.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/AEYENational VisionN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.800.99%N/A40.40%14 YearsLQDALiquidia TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.851.410.99EYENational Vision0.290.540.35LMATLeMaitre Vascular0.4816.4913.83LQDALiquidia Technologies2.082.932.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%EYENational VisionN/ALMATLeMaitre Vascular84.64%LQDALiquidia Technologies64.54%Insider OwnershipCompanyInsider OwnershipBVSBioventus33.00%EYENational Vision2.70%LMATLeMaitre Vascular9.50%LQDALiquidia Technologies26.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20082.14 million54.46 millionNot OptionableEYENational Vision13,41179.05 million76.92 millionOptionableLMATLeMaitre Vascular49022.59 million20.45 millionOptionableLQDALiquidia Technologies5085.49 million62.83 millionOptionableBVS, EYE, LMAT, and LQDA HeadlinesRecent News About These CompaniesLiquidia Technologies (NASDAQ:LQDA) Hits New 12-Month High - Here's What HappenedAugust 1 at 6:44 AM | marketbeat.comOppenheimer Keeps Their Sell Rating on Liquidia Technologies (LQDA)August 1 at 5:09 AM | theglobeandmail.comLiquidia Technologies, Inc. (NASDAQ:LQDA) CAO Sells $20,771.02 in StockJuly 31 at 8:04 PM | marketbeat.comLiquidia Technologies (LQDA) Projected to Post Quarterly Earnings on WednesdayJuly 31 at 7:58 AM | marketbeat.comLiquidia Technologies, Inc. (NASDAQ:LQDA) CAO Dana Boyle Sells 1,063 SharesJuly 31 at 7:01 AM | insidertrades.comLiquidia Technologies, Inc. (NASDAQ:LQDA) Given Consensus Rating of "Buy" by AnalystsJuly 30 at 2:47 AM | americanbankingnews.comLiquidia Technologies, Inc. (NASDAQ:LQDA) Given Average Recommendation of "Buy" by AnalystsJuly 30 at 2:45 AM | marketbeat.comLiquidia Technologies (NASDAQ:LQDA) Hits New 52-Week High - Should You Buy?July 26, 2025 | marketbeat.comInsider Selling: Liquidia Technologies, Inc. (NASDAQ:LQDA) Insider Sells 2,526 Shares of StockJuly 24, 2025 | marketbeat.comLiquidia Technologies call volume above normal and directionally bullishJuly 24, 2025 | msn.comLiquidia Technologies, Inc. (NASDAQ:LQDA) Insider Rajeev Saggar Sells 2,526 SharesJuly 24, 2025 | insidertrades.comLiquidia Technologies (NASDAQ:LQDA) Stock Price Up 10.1% - Still a Buy?July 23, 2025 | marketbeat.comLiquidia Meets 80-Plus Relative Strength Rating BenchmarkJuly 23, 2025 | msn.comLiquidia Shows Rising Relative Price Performance; Still Shy Of Key ThresholdJuly 16, 2025 | msn.comInsider Selling: Liquidia Technologies, Inc. (NASDAQ:LQDA) CAO Sells 1,193 Shares of StockJuly 16, 2025 | insidertrades.comLiquidia Technologies, Inc. (NASDAQ:LQDA) CAO Dana Boyle Sells 1,193 SharesJuly 15, 2025 | marketbeat.comLiquidia Technologies, Inc. (NASDAQ:LQDA) Insider Sells $36,785.28 in StockJuly 15, 2025 | marketbeat.comSarah Krepp Sells 2,673 Shares of Liquidia Technologies, Inc. (NASDAQ:LQDA) StockJuly 15, 2025 | marketbeat.comLiquidia Technologies, Inc. (NASDAQ:LQDA) Insider Sells $68,501.16 in StockJuly 15, 2025 | marketbeat.comLiquidia Technologies, Inc. (NASDAQ:LQDA) Insider Sells $76,069.56 in StockJuly 15, 2025 | marketbeat.comLiquidia Technologies, Inc. (NASDAQ:LQDA) General Counsel Russell Schundler Sells 7,836 SharesJuly 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines2025: A Pivotal Year for Smart Glasses As Meta Invests in Ray-BanBy Leo Miller | July 18, 2025View 2025: A Pivotal Year for Smart Glasses As Meta Invests in Ray-Ban3 Retail Stocks to Watch as Back-to-School Spending Ramps UpBy Chris Markoch | July 14, 2025View 3 Retail Stocks to Watch as Back-to-School Spending Ramps UpCrowdStrike Stock Eyes Next Move With AI in FocusBy Chris Markoch | July 29, 2025View CrowdStrike Stock Eyes Next Move With AI in FocusAES Gains 20% as Private Equity Eyes AI Hyperscale Energy PlayerBy Leo Miller | July 14, 2025View AES Gains 20% as Private Equity Eyes AI Hyperscale Energy PlayerAbbVie Stock Eyes Breakout as Pipeline and Profits GrowBy Chris Markoch | July 31, 2025View AbbVie Stock Eyes Breakout as Pipeline and Profits GrowBVS, EYE, LMAT, and LQDA Company DescriptionsBioventus NYSE:BVS$6.18 -0.34 (-5.21%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.18 0.00 (0.00%) As of 08/1/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.National Vision NASDAQ:EYE$24.21 -0.05 (-0.21%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$24.20 -0.01 (-0.04%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.LeMaitre Vascular NASDAQ:LMAT$81.04 -0.20 (-0.25%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$81.10 +0.06 (+0.07%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.Liquidia Technologies NASDAQ:LQDA$17.68 -1.01 (-5.40%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$17.85 +0.17 (+0.96%) As of 08/1/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
